• Twitter
  • Jobs
ProCURE oncology
  • HOME
  • ABOUT US
  • RESEARCH GROUP
    • Molleví’s Lab
    • Antolin’s Lab
    • Alemany’s & Piulats’s lab
    • Martínez-Balibrea’s Lab
    • Aytes’s Lab
    • Belver’s Lab
    • Pujana’s Lab
    • Menendez’s Lab
    • Sureda’s & Farre’s Lab
    • Casanovas’s Lab
    • Viñals’s lab
  • INNOVATION
  • NEWS
  • CONTACT
  • Menu Menu

NEWS

Use of the quality management system “JACIE” and outcome after hematopoietic stem cell transplantation

View in PubMed
4 de February de 2014/in Sureda's & Farre's Lab/by

Haematologica. 2014 May;99(5):908-15. doi: 10.3324/haematol.2013.096461. Epub 2014 Jan 31.

ABSTRACT

Competent authorities, healthcare payers and hospitals devote increasing resources to quality management systems but scientific analyses searching for an impact of these systems on clinical outcome remain scarce. Earlier data indicated a stepwise improvement in outcome after allogeneic hematopoietic stem cell transplantation with each phase of the accreditation process for the quality management system “JACIE”. We therefore tested the hypothesis that working towards and achieving “JACIE” accreditation would accelerate improvement in outcome over calendar time. Overall mortality of the entire cohort of 107,904 patients who had a transplant (41,623 allogeneic, 39%; 66,281 autologous, 61%) between 1999 and 2006 decreased over the 14-year observation period by a factor of 0.63 per 10 years (hazard ratio: 0.63; 0.58-0.69). Considering “JACIE”-accredited centers as those with programs having achieved accreditation by November 2012, at the latest, this improvement was significantly faster in “JACIE”-accredited centers than in non-accredited centers (approximately 5.3% per year for 49,459 patients versus approximately 3.5% per year for 58,445 patients, respectively; hazard ratio: 0.83; 0.71-0.97). As a result, relapse-free survival (hazard ratio 0.85; 0.75-0.95) and overall survival (hazard ratio 0.86; 0.76-0.98) were significantly higher at 72 months for those patients transplanted in the 162 “JACIE”-accredited centers. No significant effects were observed after autologous transplants (hazard ratio 1.06; 0.99-1.13). Hence, working towards implementation of a quality management system triggers a dynamic process associated with a steeper reduction in mortality over the years and a significantly improved survival after allogeneic stem cell transplantation. Our data support the use of a quality management system for complex medical procedures.

PMID:24488562 | PMC:PMC4008105 | DOI:10.3324/haematol.2013.096461

https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 2014-02-04 11:00:002014-02-04 11:00:00Use of the quality management system “JACIE” and outcome after hematopoietic stem cell transplantation

Filter by categories

  • Alemany’s & Piulats’s lab (133)
  • Antolin's lab (36)
  • Aytes's Lab (25)
  • Belver's Lab (25)
  • Casanovas's Lab (77)
  • Martínez-Balibrea's Lab (43)
  • Menendez's Lab (121)
  • Molleví's Lab (35)
  • Pujana's Lab (110)
  • Sin categoría (5)
  • Sureda's & Farre's Lab (312)
  • Viñals's lab (111)

Twitter

Tweets by ProcureICO
Program Against Cancer Therapeutic Resistance

CONTACT US

Campus IDIBELL
(L’Hospitalet del Llobregat)
Hospital Duran i Reynals, Gran Via 199,
L’Hospitalet del Llobregat,
Barcelona 08908
Tel. +34 93 260 7952

Campus IGTP-IJC
(Badalona)
Campus Can Ruti – IGTP – Building Muntanya,
Rd. Can Ruti, Camí de les escoles s/n,
Badalona, Barcelona 08916
Tel. +34 93 554 3069

Campus IDIBGI
(Girona)
Parc Hospitalari Martí i Julià de Salt, Dr. Castany s/n,
Salt, Girona 17190
Tel. +34 872 987 087

© Copyright - Edisenius
  • Privacy Policy
  • Cookie Policy
  • Legal Notice
Molecular biology of neuroendocrine tumors: from pathways to biomarkers and...Contrasting responses of non-small cell lung cancer to antiangiogenic therapies...
Scroll to top
Manage cookie consent
To offer the best experiences, we use technologies such as cookies to store and/or access device information. Consent to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Failure to consent, or withdrawal of consent, may adversely affect certain features and functions.
Functional Always active
Storage or technical access is strictly necessary for the legitimate purpose of allowing the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. Storage or technical access that is used exclusively for anonymous statistical purposes. Without a requirement, voluntary compliance by your Internet service provider, or additional records from a third party, information stored or retrieved solely for this purpose cannot be used to identify you.
Marketing
Storage or technical access is necessary to create user profiles to send advertising, or to track the user on a website or several websites for similar marketing purposes.
Manage options Manage services Manage {vendor_count} vendors Read more about these purposes
See preferences
{title} {title} {title}